These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 33173310)
1. Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer. Su X; Liu J; Zhang H; Gu Q; Zhou X; Ji M; Yao D Onco Targets Ther; 2020; 13():11183-11192. PubMed ID: 33173310 [TBL] [Abstract][Full Text] [Related]
2. Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Jing C; Gao Z; Wang R; Yang Z; Shi B; Hou P Am J Cancer Res; 2017; 7(4):903-912. PubMed ID: 28469962 [TBL] [Abstract][Full Text] [Related]
3. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer. Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells. Kawamura Y; Saijo K; Imai H; Ishioka C Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666 [TBL] [Abstract][Full Text] [Related]
6. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment. Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127 [No Abstract] [Full Text] [Related]
7. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells. Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886 [TBL] [Abstract][Full Text] [Related]
8. Lenvatinib for Anaplastic Thyroid Cancer. Tahara M; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Sasaki T; Suzuki T; Fujino K; Dutcus CE; Takahashi S Front Oncol; 2017; 7():25. PubMed ID: 28299283 [TBL] [Abstract][Full Text] [Related]
9. Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models. Enomoto K; Hirayama S; Kumashiro N; Jing X; Kimura T; Tamagawa S; Matsuzaki I; Murata SI; Hotomi M Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670725 [TBL] [Abstract][Full Text] [Related]
10. Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Wang R; Yamada T; Arai S; Fukuda K; Taniguchi H; Tanimoto A; Nishiyama A; Takeuchi S; Yamashita K; Ohtsubo K; Matsui J; Onoda N; Hirata E; Taira S; Yano S Mol Cancer Ther; 2019 May; 18(5):947-956. PubMed ID: 30926637 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. Tohyama O; Matsui J; Kodama K; Hata-Sugi N; Kimura T; Okamoto K; Minoshima Y; Iwata M; Funahashi Y J Thyroid Res; 2014; 2014():638747. PubMed ID: 25295214 [TBL] [Abstract][Full Text] [Related]
13. Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration. Ferrari SM; La Motta C; Elia G; Ragusa F; Ruffilli I; Quattrini L; Paparo SR; Piaggi S; Patrizio A; Ulisse S; Baldini E; Materazzi G; Fallahi P; Antonelli A Front Endocrinol (Lausanne); 2018; 9():764. PubMed ID: 30619094 [TBL] [Abstract][Full Text] [Related]
14. Augmentation of lenvatinib efficacy by topical treatment of Kishikawa M; Inoue J; Hamamoto H; Kobayashi K; Asakage T; Inazawa J Biochem Biophys Rep; 2021 Jul; 26():101009. PubMed ID: 34027135 [TBL] [Abstract][Full Text] [Related]
15. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction. Koyama S; Miyake N; Fujiwara K; Morisaki T; Fukuhara T; Kitano H; Takeuchi H Eur Thyroid J; 2018 Jun; 7(3):139-144. PubMed ID: 30023346 [TBL] [Abstract][Full Text] [Related]
16. Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT. Aoyama M; Takizawa H; Otani T; Inoue S; Kawakita N; Tsuboi M; Bando Y; Uehara H; Kondo K; Tangoku A Oncol Rep; 2020 Oct; 44(4):1709-1716. PubMed ID: 32945510 [TBL] [Abstract][Full Text] [Related]
17. Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report. Yamazaki H; Masudo K; Kanada S; Inayama Y; Hayashi H; Fujii Y; Rino Y Surg Case Rep; 2023 Mar; 9(1):38. PubMed ID: 36920674 [TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan. Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927 [TBL] [Abstract][Full Text] [Related]
19. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098 [TBL] [Abstract][Full Text] [Related]
20. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]